RSVA 405

Research use only, not for human use.

RSVA 405 is an AMPK activator (EC50 = 1 μM), and is STAT3 inhibitor.

RSVA 405 is an AMPK activator (EC50 = 1 μM), and is STAT3 inhibitor.

RSVA405 (0.2-2 μM; 24 h) inhibits adipocyte differentiation.RSVA405 (0.2-2 μM; 24 h) significantly inhibits the expression of peroxisome proliferator-activated receptor (PPAR)-γ, fatty acid synthase (FAS) and fatty acid binding protein 4 (aP2) in 3T3-L1 cells.RSVA405 (1-3 μM; 16 h) inhibits LPS-induced STAT3 activity, intracellular signaling, and cytokine response in activated RAW 264.7 macrophages.RSVA405 (1-3 μM; 24 h) inhibits mTOR, induces autophagy, and facilitates the lysosomal degradation of Aβ, with an EC50 of ～1 μM in APP-HEK293 cells.Cell Viability Assay Cell Line:3T3-L1 preadipocytes Concentration:0.2, 0.5, 1, 2 μM Incubation Time:24 h Result:Increased the phosphorylation of AMPK and its substrate acetyl-CoA carboxylase (ACC).Inhibited the accumulation of lipid droplets in a dose-dependent manner, with an IC50 of 0.5 μM.

RSVA405 (3 mg/kg; i.p.) attenuates renal injury and protects renal function after ischemia-reperfusion (I/R) in rats.RSVA405 (20-100 mg/kg/d; p.o. for 11 weeks) significantly reduces the body weight gain of mice fed a high-fat diet. Animal Model:Male Sprague-Dawley rats (300-350 g) are induced I/R injury Dosage:3 mg/kg Administration:I.p. one hour before inducing I/R injury Result:Decreased the levels of creatinine and blood urea nitrogen (BUN), by 35.8% and 44.3% in serum, respectively.Decreased the levels of aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) by 33.0% and 59.8% in serum, respectively.

——

JAK/STAT Signaling

STAT

STAT3|AMPK

——

——

140405-36-3

312.37

C17H20N4O2

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (400.17 mM)

CCN(CC)C1=CC(O)=C(C=NNC(=O)C2=CC=NC=C2)C=C1

——

(-20℃)

With Ice Pack

≥ 2 years